Abstract

Detrimental impact of chemotherapy dose reduction or discontinuation in early stage triple-negative breast cancer treated with pembrolizumab and neoadjuvant chemotherapy: A multi-center experience

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call